As always, we spotlight peer-reviewed studies and changes to official guidance from the week. Much of this work, (vaccines, diagnostics, prevention, and trial infrastructure) rests on sustained public funding (often including NIH). At time of writing, the government is currently shutdown and new NIH funding for life-saving interventions is not being reviewed. Nothing here is medical advice; talk to your clinician before changing meds or treatments.
🧠 Mild concussion, lingering symptoms: who stays at risk?
What’s new: An ER cohort study mapped factors linked to 30-day persistent symptoms after mild traumatic brain injury (mTBI).
Why it matters: Helps clinicians and patients spot who needs closer follow-up after “just a concussion.”
Source: JAMA Network Open
🏃♀️ Normal BMI but bigger waist? Risks climb.
What’s new: Globally, abdominal obesity with normal BMI was common and tied to worse cardiometabolic outcomes.
Why it matters: Tape measures matter—waist can flag risk that BMI alone misses.
Source: JAMA Network Open
👩🔬 Diverse research teams, better representation in trials
What’s new: Teams with more women researchers were associated with higher enrollment of women in clinical trials.
Why it matters: Who designs studies can shape who benefits from evidence.
Source: JAMA Network Open
🧫 Where Americans are (and aren’t) getting screened for cancer
What’s new: County-level maps from 1997–2019 show geographic hot/cold spots in breast, cervical, and colorectal screening—and the community factors tied to them.
Why it matters: Pinpoints places to boost access and save lives with routine screening.
Source: JAMA Network Open
🧬 Targeted option for HER2-mutant lung cancer
What’s new: Sevabertinib showed activity in advanced HER2-mutant NSCLC in a NEJM original article.
Why it matters: Expands the toolkit for a hard-to-treat mutation.
Source: New England Journal of Medicine
🧠 Narcolepsy & mortality: reassuring news
What’s new: In a national Taiwanese cohort, narcolepsy was not linked to higher all-cause or cause-specific mortalityversus matched controls/siblings over long follow-up.
Why it matters: Supports focusing care on safety & symptom control rather than excess mortality risk.
Source: JAMA Network Open
🧠🧪 MRI “aging clocks” across organs
What’s new: Scientists combined MRI with omics to build organ-specific aging clocks tied to mortality and disease risk.
Why it matters: May enable earlier prevention by spotting which organs are aging fastest.
Source: Nature Medicine
🫀 What happens as life ends — measured in real time
What’s new: Researchers monitored brain & heart signals during human circulatory arrest, detailing the physiology of dying and potential markers.
Why it matters: Could guide resuscitation, time-of-death determination, and organ donation protocols.
Source: Nature Medicine
🧠 A 5-minute digital test helps spot Alzheimer’s risk
What’s new: A Nature Medicine Research Briefing reports that a brief, self-administered digital cognitive test (BioCog), combined with blood biomarkers, outperformed typical clinic screens for detecting impairment.
Why it matters: Quicker, more accurate primary-care detection could speed diagnosis and support.
Source: Nature Medicine
Stay Curious,
Science Rabbit Team
Leave a Reply